MannKind Expands Afrezza’s Pediatric and Gestational Diabetes Use with New ADA 2026 Data
Event summary
- MannKind presented new data at ADA 2026 showing Afrezza’s efficacy in pediatric diabetes, gestational diabetes, and compatibility with automated insulin delivery systems.
- Recent FDA approval (May 29, 2026) expanded Afrezza’s use to children aged 6 and older with type 1 and type 2 diabetes.
- Studies highlighted Afrezza’s comparable glycemic control to rapid-acting analogs with improved treatment satisfaction in pediatric patients.
- Exploratory analysis suggested potential benefits of Afrezza in gestational diabetes and with automated insulin delivery systems.
The big picture
MannKind’s latest data reinforces Afrezza’s role in expanding treatment options for diabetes, particularly in underserved pediatric and gestational populations. The strategic focus on integrating Afrezza with automated insulin delivery systems aligns with broader industry trends toward personalized and tech-enabled diabetes management. The recent FDA approval and positive clinical findings position MannKind to capture a larger share of the growing pediatric diabetes market.
What we're watching
- Pediatric Market Expansion
- How MannKind will leverage the recent FDA approval to penetrate the pediatric diabetes market.
- Integration with AID Systems
- Whether Afrezza’s compatibility with automated insulin delivery systems will drive adoption among adult and pediatric patients.
- Gestational Diabetes Potential
- The pace at which Afrezza could gain approval and market share in gestational diabetes treatment.
Related topics